Tenderwize
Zurück zur Suche

Open-house rebate agreements for colchicine

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Aug 03, 2027 · 340 days left·Open·Supplies·Framework
Registrieren zum SpeichernOpen documents
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Colchicin, ATC M04AC01

56/100

Opportunity Score

Needs reviewMedium complexity
SuppliesFrameworkOpen
Warum diese Bewertung?

Chance

56 / 100

Komplexität

48 / 100

Risikofaktoren

Submitting the contract documents in the wrong DTVP area is explicitly prohibited; they must be sent via the communicat...

To obtain the next monthly start date, complete documents must be received by the 3rd of the month; for paper filings...

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Sep 2027
  • Non-exclusive rebate agreements for pharmaceutical products containing colchicine (ATC M04AC01).
  • Open-house model with identical, non-individually negotiable contract terms for all eligible pharmaceutical companies.
Vollständige Zusammenfassung anzeigen

Open-house supply arrangement for pharmaceutical products: AOK Bayern seeks non-exclusive rebate agreements for colchicine (ATC M04AC01) with all interested pharmaceutical companies that meet the stated suitability requirement. This is explicitly described as an open-house model, not a competitive open procedure, with no selection among bidders and no negotiated contract terms. The contract period runs from 2025-10-01 to 2027-09-30, and applications can be submitted until 2027-08-03 12:00 local time; for monthly start dates, complete documents must arrive by the 3rd of the month, with paper originals by the 10th if scanned in advance.

Risiken

Submitting the contract documents in the wrong DTVP area is explicitly prohibited; they must be sent via the communicat...

To obtain the next monthly start date, complete documents must be received by the 3rd of the month; for paper filings...

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Eligibility

  • Only pharmaceutical companies are eligible as potential contract partners.

Administrative

  • A signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit) must be submitted.
  • The contract must be submitted completed and signed; signatory authority must be evidenced by the commercial register extract or a power of attorney.

Auftraggeber

Ort

München, DEU

Website

www.aok.de

Auftraggeberprofil

Profil öffnen

Kennung

DE811695320

Tätigkeit

Health

Lose (1)

LOT-0001

Open-house rebate agreements for colchicine

Supply of pharmaceutical products under an open-house rebate agreement for the active substance colchicine (ATC M04AC01). The lot is for non-exclusive, identical contract terms for interested pharmaceutical companies. Place of performance is Germany, Bavaria (DE212).

SuppliesFrameworkEU fundedElectronic submission

Ort

DE212, Germany

Dauer

Sep 2025 - Sep 2027

Kategorie

Pharmaceutical products

Frist

Deadline Aug 03, 2027

Vergabedetails

Veröffentlichungsdatum
13 Aug 2025
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
532530-2025

Dokumente (2)

Vergabedokument 1Einreichungsportal 1

Ähnliche Ausschreibungen

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30